Reduce, Refine, Replace. Developed over 50 years ago, the 3Rs provide a framework that urges researchers to think carefully about methods used to investigate scientific questions. In this episode of EASL Studio, we took a closer look at the third R, Replace. With the World Day for Laboratory Animals fast approaching, we discussed how to propel liver cell biology into the third dimension.

• What are the advantages of 3D cultures?
• Can liver cell types be studied in representative manner using 3D cultures?
• More importantly, which part of animal research can be replaced by 3D cell culture experiments?

This and more in EASL Studio: YI Choice.

Read more

All EASL Studio Podcasts are available on EASL Campus.

Discover this EASL Studio Podcast highlighting the recently published EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Join the faculty as they discuss:

• What effects do anticoagulants have on survival and liver related events in cirrhosis?
• What are the mechanisms of action?
• What type of anticoagulants should be used in patients with cirrhosis?

Read more

All EASL Studio Podcasts are available on EASL Campus.

In recent years social media has become a powerful tool, not only for science dissemination, but also for discussing data and networking.

• What is the impact of dissemination via social media?
• How is social media changing the way data is communicated?
• Should social media activity be considered a professional endeavour?

Listen to this podcast to find out.

Read more

All EASL Studio Podcasts are available on EASL Campus.

Discover this EASL Studio podcast discussing the Baveno Consensus started over 30 years ago with the aim of reviewing current diagnostic and therapeutic strategies and producing updated definitions.

But, with the extension of indication of non-selective beta blockers, has the consensus gone too far?

• Is there enough evidence for their use in already decompensated patients?
• How safe are they in this patient population?
• What do we know about the effects on refractory ascites? Circulatory dysfunction?

Read more

All EASL Studio Podcasts are available on EASL Campus.

This podcast is based on the EASL Studio episode hosted on the occasion of the Rare Liver Diseases Month.

This episode focused on rare liver diseases, in particular, Progressive Familial Intrahepatic Cholestasis (PFIC). Discussions covered:

• Clinical presentation of PFIC
• Current therapeutic options
• The introduction of IBAT/ASBT inhibitors and their impact
• Clinical trials
• Orphan drugs approved for PFIC
• Interview with EMA on the orphan drug programme

This EASL Studio episode was supported by Albireo Pharma and Mirum Pharmaceuticals.

Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2e1-new-treatment-options-hereditary-cholestasis-syndromes-game-changer

In this EASL Studio Podcast, a very special interview with Prof. Stephan Urban talking about his journey of the discovery and development of the first HBV/HDV entry inhibitor.

• Where did the story begin and what were the major breakthroughs and challenges?
• What are the mechanisms of viral entry inhibitors and how it differs from direct acting antivirals mode of action?
• How does it impact the future of HBV/HDV treatment landscape?

This project has been made possible with the provision of a financial grant from Gilead Sciences Europe Ltd.
EASL has received no input from Gilead with regard to the content of this programme.

Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2e3-interview-stephan-urban-bench-bedside-process-developing-first

In this podcast conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions on liver cancer raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.

In this episode, Professor Markus Cornberg is joined by Dr Christiane Eberhardt and Professor Daniel Shouval to answer a range of questions raised by EASL’s Patient Synergies regarding the recently approved COVID-19 vaccinations.

They address topics including the reasons for the rapid development of the vaccines, whether immunocompromised liver transplant patients should receive the vaccine, real-world data from vaccination programmes worldwide and the potential duration of immunity.

Discover on our website more educational materials on COVID-19 and the liver.